Open AccessCardiovascular Safety and Superiority of Anti-Obesity Medications
Author(s) -
Muath Alobaida,
Abdullah Alrumayh,
Ayodipupo Sikiru Oguntade,
Faez Al-Amodi,
Mwango Bwalya
Publication year - 2021
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s311359
Subject(s) - medicine , diabetes mellitus , clinical trial , adverse effect , obesity , food and drug administration , intensive care medicine , safety profile , weight loss , type 2 diabetes , pharmacology , endocrinology
Over the past few decades, several anti-obesity medications have demonstrated an association with adverse cardiovascular outcomes, leading to their market withdrawal. This has caused researchers to investigate the cardiovascular safety of such medications in cardiovascular outcome trials. However, the data from these trials are limited, and their outcomes are not promising. Therefore, the aim of this review is to provide an overview of the current and past Food and Drug Administration-approved medications for weight loss, including novel diabetes medications (glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) and non-diabetes medications, and to highlight the current designs of cardiovascular outcome trials and their importance in the evaluation of the overall safety concerns associated with these anti-obesity medications. The limitations of the trials and opportunities for improvement were also evaluated. Finally, we also briefly describe cardiovascular safety and risks in this review.